Reshma Kewalramani, Vertex CEO (Barry Chin/The Boston Globe via Getty Images)

Ver­tex touts Cas­gevy sick­le cell launch as blue­bird makes progress with ri­val Lyf­ge­nia

Ver­tex said it’s mak­ing strong progress bring­ing its CRISPR Ther­a­peu­tics-part­nered gene ther­a­py to pa­tients af­ter a land­mark ap­proval for sick­le cell dis­ease in De­cem­ber. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.